Cargando…

Pim2 is important for regulating DNA damage response in multiple myeloma cells

Pan proviral integrations of Moloney virus (PIM) inhibition in multiple myeloma (MM) results in reduced cell viability in tested human-derived MM cell lines and reduces tumor burden in xenograft mouse models, making PIMs important therapeutic targets for the disease. PIM kinase inhibitors are curren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramachandran, J, Santo, L, Siu, K T, Panaroni, C, Raje, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022183/ https://www.ncbi.nlm.nih.gov/pubmed/27564460 http://dx.doi.org/10.1038/bcj.2016.73

Ejemplares similares

It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Choa, Ruth, et al.
Publicado: (2023)

PIM Kinases in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2021)

Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)

Pim-2 Kinase Regulates Energy Metabolism in Multiple Myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2022)

An overview of pim kinase as a target in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
por: Mori, Tomoaki, et al.
Publicado: (2021)

Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
por: Petrilla, Cole, et al.
Publicado: (2023)

Pim Kinases: Important Regulators of Cardiovascular Disease
por: Nock, Sophie, et al.
Publicado: (2023)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)

DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
por: Saitoh, Takayuki, et al.
Publicado: (2021)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

P811: PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
por: Nair, Jayakumar R., et al.
Publicado: (2016)

OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew, et al.
Publicado: (2021)

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew R., et al.
Publicado: (2021)

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
por: Herrero, Ana Belén, et al.
Publicado: (2017)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Lifestyle considerations in multiple myeloma
por: Shapiro, Yael N., et al.
Publicado: (2021)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
por: Swan, Dawn, et al.
Publicado: (2020)

NBS1 and multiple regulations of DNA damage response
por: Komatsu, Kenshi
Publicado: (2016)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Myeloma–Bone Interaction: A Vicious Cycle via TAK1–PIM2 Signaling
por: Harada, Takeshi, et al.
Publicado: (2021)

PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells
por: Siu, Allan, et al.
Publicado: (2011)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

The role of PIM1/PIM2 kinases in tumors of the male reproductive system
por: Jiménez-García, Manuel Pedro, et al.
Publicado: (2016)

Expression and Importance of TMED2 in Multiple Myeloma Cells
por: Ge, Xueling, et al.
Publicado: (2020)

Expression and ERG regulation of PIM kinases in prostate cancer
por: Eerola, Sini K., et al.
Publicado: (2021)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
por: Talluri, Srikanth, et al.
Publicado: (2021)

The treatment of multiple myeloma--an important MRC trial.
por: Johnson, P. W., et al.
Publicado: (1994)

TSPYL2 Is Important for G1 Checkpoint Maintenance upon DNA Damage
por: Tao, Kin Pong, et al.
Publicado: (2011)

Multicenter validation of PIM3 and PIM2 in Brazilian pediatric intensive care units
por: Genu, Daniel Hilário Santos, et al.
Publicado: (2022)

Sex specific regulation of TSPY-Like 2 in the DNA damage response of cancer cells
por: Cardano, Miriana, et al.
Publicado: (2023)

Bufalin induces DNA damage response under hypoxic condition in myeloma cells
por: Fujii, Eri, et al.
Publicado: (2018)

Linac4 PIMS
por: Pantelia, Anna
Publicado: (2014)

DNA2—An Important Player in DNA Damage Response or Just Another DNA Maintenance Protein?
por: Pawłowska, Elzbieta, et al.
Publicado: (2017)

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
por: Mithraprabhu, Sridurga, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_813kebn4pn50nt4iuhpik4kh4m